AKT1 and polycystic ovary syndrome: Research has shown that BBR can inhibit the level of inflammatory factors in the GCs of patients with PCOS, increase the levels of AMPK (Adenosine 5‘-monophosphate (AMP)-activated protein kinase) mRNA and IRS-1 (insulin receptor substrate 1) mRNA, and reduce the level of mTOR (mammalian target of rapamycin) mRNA [5], and can activate the PI3K/AKT (phosphatidylinositol 3-kinase/ protein kinase B) signaling pathway and regulate the MAPK signaling pathway [6], so that can achieve the prevention and treatment of PCOS and the effect of protection of GCs.